Nonatherosclerotic PAD: Approach to Exertional Pain in the Lower Extremities | springermedicine.com

Springer Medicine

Top

Current Cardiology Reports

Published in:

01-08-2015 | Peripheral Vascular Disease (MR Jaff, Section Editor)

Nonatherosclerotic PAD: Approach to Exertional Pain in the Lower Extremities

Authors: Ari J. Mintz, Ido Weinberg

Published in: Current Cardiology Reports | Issue 8/2015

Login to get access

Abstract

Atherosclerotic peripheral artery disease is the most common cause of intermittent claudication. Nonatherosclerotic peripheral artery disease is a heterogeneous collection of diseases affecting the extracoronary arteries which is not due to atherosclerosis. These diseases include, but are not limited to, popliteal artery entrapment syndrome, cystic adventitial disease, external iliac endofibrosis, and thromboangiitis obliterans. Due to its relatively low prevalence, nonatherosclerotic peripheral artery disease may be misdiagnosed leading to the mismanagement of potentially treatable conditions. The proper and timely diagnosis of these conditions is paramount to the prevention of adverse outcomes as treatments widely vary. The diagnostic approach to patients presenting with intermittent claudication must take into account both atherosclerotic as well as nonatherosclerotic causes of peripheral artery disease making the differential vital to clinical practice.

1.

Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110:738–43.PubMedCrossRef

2.

Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral artery disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.PubMedCrossRef

3.

Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. German Epidemiologic Trial on Ankle Brachial Index Study Group; mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.PubMedCrossRef

4.

Weinberg I, Jaff MR. Nonatherosclerotic arterial disorders of the lower extremities. Circulation. 2012;126:213–22.PubMedCrossRef

5.

Levien LJ, Veller MG. Popliteal artery entrapment syndrome: more common than previously recognized. J Vasc Surg. 1999;30:587–98.PubMedCrossRef

6.

di Marzo L, Cavallaro A. Popliteal vascular entrapment. World J Surg. 2005;29 Suppl 1:S43–5.PubMedCrossRef

7.

Bouhoutos J, Daskalakis E. Muscular abnormalities affecting the popliteal vessels. Br J Surg. 1981;68:501–6.CrossRef

8.

Pillai J. A current interpretation of popliteal vascular entrapment. J Vasc Surg. 2008;48:61S–5S.PubMedCrossRef

9.

Causey MW, Singh N, Miller S. Intraoperative duplex and functional popliteal entrapment syndrome: strategy for effective treatment. Ann Vasc Surg. 2010;24:556–61.PubMedCrossRef

10.

Sinha S, Houghton J, Holt PJ, Thompson MM, Loftus IM, Hinchliffe RJ. Popliteal entrapment syndrome. J Vasc Surg. 2012;55:252–262.e30.PubMedCrossRef

11.

Angeli AA, Angeli DA, Aggeli CA, Mandrekas DP. Chronic lower leg swelling caused by isolated popliteal venous entrapment. J Vasc Surg. 2011;54:851–3.PubMedCrossRef

12.

Korngold EC, Jaff MR. Unusual causes of intermittent claudication: popliteal artery entrapment syndrome, cystic adventitial disease, fibromuscular dysplasia, and endofibrosis. Curr Treat Options Cardiovasc Med. 2009;11:156–66.PubMedCrossRef

13.

Akkersdijk WL, de Ruyter JW, Lapham R, Mali W, Eikelboom BC. Colour duplex ultrasonographic imaging and provocation of popliteal artery compression. Eur J Vasc Endovasc Surg. 1995;10:342–5.PubMedCrossRef

14.

Holden A, Merrilees S, Mitchell N, et al. Magnetic resonance imaging of popliteal artery pathologies. Eur J Radiol. 2008;67:159–68.PubMedCrossRef

15.

Marzo L, Cavallaro A, Mingoli A, Sapienza P, Tedesco M, Stipa S. Popliteal artery entrapment syndrome: the role of early diagnosis and treatment. Surgery. 1997;122:26–31.PubMedCrossRef

16.

Tomasian A, Lai C, Finn JP, et al. Cystic adventitial disease of the popliteal artery: features on 3T cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:38.PubMedCentralPubMedCrossRef

17.

Steffen CM, Ruddle A, Shaw JF. Adventitial cystic disease: multiple cysts causing common femoral artery occlusion. Eur J Vasc Endovasc Surg. 1995;9:118–9.PubMedCrossRef

18.

França M, Pinto J, Machado R, et al. Case 157: bilateral adventitial cystic disease of the popliteal artery. Radiology. 2010;255(2):655–60.PubMedCrossRef

19.

Motaganahalli RL, Pennell RC, Mantese VA, Westfall SG. Cystic adventitial disease of the popliteal artery. J Am Coll Surg. 2009;209:541.PubMedCrossRef

20.

Cassar K, Engeset J. Cystic adventitial disease: a trap for the unwary. Eur J Vasc Endovasc Surg. 2005;29:93–6.PubMedCrossRef

21.

Flanigan DP, Burnham SJ, Goodreau JJ, Bergan JJ. Summary of cases of adventitial cystic disease of the popliteal artery. Ann Surg. 1979;189:165–75.PubMedCentralPubMedCrossRef

22.

Meka M, Hamrick MC, Wixon CL. Cystic adventitial disease of the popliteal artery: a potential cause of lower extremity claudication. Am Surg. 2009;75:86–9.PubMed

23.

Rai S, Davies RS, Vohra RK. Failure of endovascular stenting for popliteal cystic disease. Ann Vasc Surg. 2009;23:410 e1–e5.PubMedCrossRef

24.

Chevalier JM, Enon B, Walder J, et al. Endofibrosis of the external iliac artery in bicycle racers: an unrecognized pathological state. Ann Vasc Surg. 1986;1:297–303.PubMedCrossRef

25.

Kral CA, Han DC, Edwards WD, Spittell PC, Tazelaar HD, Cherry Jr KJ. Obstructive external iliac arteriopathy in avid bicyclists: new and variable histopathologic features in four women. J Vasc Surg. 2002;36:565–70.PubMedCrossRef

26.

Rousselet M, Saint-Andre J, L'Hoste P. Stenotic intimal thickening of the external iliac artery in competition cyclists. Hum Pathol. 1990;21:524–9.PubMedCrossRef

27.

Taylor AJ, George KP. Exercise induced leg pain in young athletes misdiagnosed as pain of musculo-skeletal origin. Man Ther. 2001;6:48–52.PubMedCrossRef

28.

Abraham P, Chevalier JM, Saumet JL. External iliac artery endofibrosis: a 40-year course. J Sports Med Phys Fitness. 1997;37:297–300.PubMed

29.

Alimi YS, Accrocca F, Barthelemy P, Hartung O, Dubuc M, Boufi M. Comparison between duplex scanning and angiographic findings in the evaluation of functional iliac obstruction in top endurance athletes. Eur J Vasc Endovasc Surg. 2004;28:513–9.PubMedCrossRef

30.

Abraham P, Leftheriotis G, Bourre Y, Chevalier JM, Saumet JL. Echography of external iliac artery endofibrosis in cyclists. Am J Sports Med. 1993;21:861–3.PubMedCrossRef

31.

Lomis NN, Miller FJ, Whiting JH, Giuliano AW, Yoon HC. Exercise-induced external iliac artery intimal fibrosis: confirmation with intravascular ultrasound. J Vasc Interv Radiol. 2000;11:51–3.PubMedCrossRef

32.

Maree AO, Ashequl Islam M, Snuderl M, et al. External iliac artery endofibrosis in an amateur runner: hemodynamic, angiographic, histopathological evaluation and percutaneous revascularization. Vasc Med. 2007;12:203–6.PubMedCrossRef

33.

Slovut DP, Olin JW. Fibromuscular dysplasia. N Engl J Med. 2004;350:1862–71.PubMedCrossRef

34.

Cragg AH, Smith TP, Thompson BH, Maroney TP, Stanson AW, Shaw GT, et al. Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. Radiology. 1989;172:145–7.PubMedCrossRef

35.••

O’Connor SC, Gornik HL. Recent developments in the understanding and management of fibromuscular dysplasia. J Am Heart Assoc. 2014;3:e001259. This paper provides an updated description on the evolving nomenclature of fibromuscular dysplasia as well as updated prevalence data from recent registries.PubMedCentralPubMedCrossRef

36.

Harrison Jr EG, McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension. Mayo Clin Proc. 1971;46(3):161–7.PubMed

37.

Gray BH, Young JR, Olin JW. Miscellaneous arterial diseases. In: Young JR, Olin JW, Bartholomew JR, editors. Peripheral vascular diseases. 2nd ed. St. Louis: Mosby-Yearbook; 1996. p. 425–40.

38.

Sauer L, Reilly LM, Goldstone J, Ehrenfeld WK, Hutton JE, Stoney RJ. Clinical spectrum of symptomatic external iliac fibromuscular dysplasia. J Vasc Surg. 1990;12:488–96.PubMedCrossRef

39.

Begelman SM, Olin JW. Fibromuscular dysplasia. Curr Opin Rheumatol. 2000;12:41–7.PubMedCrossRef

40.

Das CJ, Neyaz Z, Thapa P, Sharma S, Vashist. Fibromuscular dysplasia of the renal arteries: a radiological review. Int Urol Nephrol. 2007;39:233–8.PubMedCrossRef

41.

Gowda MS, Loeb AL, Crouse LD, Kramer PH. Complementary roles of color-flow duplex imaging and intravascular ultrasound in the diagnosis of renal artery fibromuscular dysplasia: should renal arteriography serve as the “gold standard”? J Am Coll Cardiol. 2003;41:1305–11.PubMedCrossRef

42.

Lassiter FD. The string-of-beads sign. Radiology. 1998;206(2):437–8.PubMedCrossRef

43.

Pamell AP, Loose HW, Chamberlain K. Fibromuscular dysplasia of the external iliac artery: treatment by percutaneous transluminal angioplasty. Br J Radiol. 1988;61:1080–2.CrossRef

44.

Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension. 2010;56:525–32.PubMedCrossRef

45.

Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003;349:160–9.PubMedCrossRef

46.

Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65(7):936–41.PubMedCentralPubMedCrossRef

47.

Watts R, Al-Taiar A, Mooney J, Scott D, MacGregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology. 2009;48:1008–11.PubMedCrossRef

48.

Seko Y. Takayasu arteritis. Insights into immunopathology. Jpn Heart J. 2000;41:15–26.PubMedCrossRef

49.

Connolly JE, Wilson SE, Lawrence PL, Fujitani RM. Middle aortic syndrome: distal thoracic and abdominal coarctation, a disorder with multiple etiologies. J Am Coll Surg. 2002;75:110–7.

50.

Arend WP, Michel BA, Bloch DA, Hunder GG, Calobrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129–32.PubMedCrossRef

51.

Gonzalex-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalex-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–61.CrossRef

52.

Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis [review]. Arthritis Rheum. 1999;42:844–53.PubMedCrossRef

53.

Kermani TA, Matteson EL, Hunder GC, Warrington KJ. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol. 2009;36:2277–83.PubMedCrossRef

54.

Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–8.PubMedCrossRef

55.

Seyahi E, Yurdakul S. Behcet’s syndrome and thrombosis. Mediterr J Hematol Infect Dis. 2011;3(1), e2011026.PubMedCentralPubMedCrossRef

56.

Yurdakul S, Yazici Y. Epidemiology of Behçet’s syndrome and regional differences in disease expression. In: Yazici Y, Yazici H, editors. Behçet’s syndrome. 1st ed. New York: Springer; 2010. p. 35–52.CrossRef

57.

Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med. 1999;341:1284–91.PubMedCrossRef

58.

International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335(8697):1078–80.

59.

Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76. doi:10.1097/00005792-200301000-00006.CrossRef

60.

Fresko I, Melikoglu M, Tunc R, et al. Behcet’s syndrome: pathogenesis, clinical manifestations and treatment in vasculitis. In: Gene V, Ball S, Bridges Louis, editors. 1st edition. Oxford University Press; USA 2002.

61.

Melikoglu M, Ugurlu S, Tascilar K, et al. Large vessel involvement in Behcet’s syndrome: a retrospective survey. Ann Rheum Dis. 2008;67(Suppl II):67.

62.

Buckley A, Southwood T, Culham G, Nadel H, Malleson P, Petty R. The role of ultrasound in Takayasu’s arteritis. J Rheumatol. 1991;18:1073–80.PubMed

63.

Nicoletti G, Mannarella C, Nigro A, Sacco A, Olivieri I. The “macaroni sign” of Takayasu’s arteritis. J Rheumatol. 2009;36:2042–3.PubMedCrossRef

64.

Gotway MB, Araoz PA, Macedo TA, Stanson AW, Higgins SB, Ring EJ, et al. Imaging findings in Takayasu’s arteritis. Am J Roentgenol. 2005;184:1945–50.CrossRef

65.

Arnaud L, Haroche K, Malek Z, Archambaud F, Gambotti L, Grimon G, et al. Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum. 2009;60:1193–200.PubMedCrossRef

66.

Ogino H, Matsuda H, Minatoya K, Sasaki H, Tanaka H, Matsumura Y, et al. Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation. 2008;118:2738–47.PubMedCrossRef

67.•

Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51:151–6. This study described successful findings of a new treatment approach to medium and large vessel vasculitis with the anti-IL-6 receptor antibody tocilizumab.CrossRef

68.

Pande RL, Beckman JA. Systemic vasculitides. In: Jaff MR, White CJ, editors. Vascular disease: diagnostic and therapeutic approaches. Minneapolis: Cardiotext; 2011. p. 341–63. Print.

69.

Buerger L. Landmark publication from the American Journal of the Medical Sciences, ‘thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene’. 1908. Am J Med Sci. 2009;337:274.PubMedCrossRef

70.

Combemale P, Consort T, Denis-Thelis L, et al. Cannabis arteritis. Br J Dermatol. 2005;152:166.PubMedCrossRef

71.

Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343:864.PubMedCrossRef

72.

Salimi J, Tavakkoli H, Salimzadeh A, et al. Clinical characteristics of Buerger’s disease in Iran. J Coll Phys Surg Pak. 2008;18:502.

73.

Sasajima T, Kubo Y, Inaba M, Goh K, Azuma N. Role of infrainguinal bypass in Buerger’s disease: an eighteen year experience. Eur J Vasc Endovasc Surg. 1997;13:186–92.PubMedCrossRef

74.

Piazza G, Creager MA. Thromboangiitis obliterans. Circulation. 2010;121:1858.PubMedCentralPubMedCrossRef

75.

Fiessinger N, Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischemia of thromboangiitis obliterans: the TAO study. Lancet. 1990;335:555–7.PubMedCrossRef

76.

The European TAO Study Group. Oral iloprost in the treatment of thromboangiitis obliterans (Buerger’s disease): a double-blind, randomized, placebo-controlled trial. Eur J Vasc Endovasc Surg. 1998;15:300–7.CrossRef

77.

Shindo S, Matsumoto H, Ogata K, Kubota K, Kojima A, Ishimoto T, et al. Arterial reconstruction in Buerger’s disease: bypass to disease free collaterals. Int Angiol. 2002;21:228–32.PubMed

78.

Hislop M, Tierney P, O’Brien M, Mahony N. Chronic exertional compartment syndrome: the controversial “fifth” compartment of the leg. Am J Sports Med. 2003;31:770–6.PubMed

79.

Schep G, Schmikli SL, Bender MH, Mosterd WL, Hammacher ER, Wijn PF. Recognising vascular causes of leg complaints in endurance athletes. Part 1: validation of a decision algorithm. Int J Sports Med. 2002;23:313–21.PubMedCrossRef

80.

Perlowski AA, Jaff MR. Vascular disorders in athletes. Vasc Med. 2010;15:469–79.PubMedCrossRef

81.

Detmer DE. Diagnosis and management of chronic compartment syndrome of the leg. Semin Orthop. 1988;3:223.

82.•

Waterman BR, Liu J, Newcomb R, Schoenfeld AJ, Orr JD, Belmont PJ. Risk factors for chronic exertional compartment syndrome in a physically active military population. Am J Sports Med. 2013;41:2545–9. This study provided a large sample of participants in attempts to establish a previously unknown prevalence of chronic exertional compartment syndrome a physically active population.PubMedCrossRef

83.

Glorioso J, Wilckens J. Exertional leg pain. In: O’Connor F, Wilder R, editors. The textbook of running medicine. New York: McGraw-Hill; 2001. p. 181–98.

84.

Hutchinson M. Chronic exertional compartment syndrome. Br J Sports Med. 2011;45:952–3.PubMedCrossRef

85.

Edwards P, Myerson MS. Exertional compartment syndrome of the leg: steps for expedient return to activity. Phys Sports Med. 1996;24:31–46.CrossRef

86.

Detmer DE, Sharpe K, Sufit RL, Girdley FM. Chronic compartment syndrome: diagnosis, management, and outcomes. Am J Sports Med. 1985;13:162–70.PubMedCrossRef

87.

Touliopolous S, Hershman EB. Lower leg pain. Diagnosis and treatment of compartment syndromes and other pain syndromes of the leg. Sports Med. 1999;27:193–204.PubMedCrossRef

88.

Pedowitz RA, Hargens AR, Mubarak SJ, Gershuni DH. Modified criteria for the objective diagnosis of chronic compartment syndrome of the leg. Am J Sports Med. 1990;18:35.PubMedCrossRef

89.

Tzortziou V, Maffulli N, Padhiar N. Diagnosis and management of chronic exertional compartment syndrome (CECS) in the United Kingdom. Clin J Sport Med. 2006;16:209.PubMedCrossRef

90.

Rorabeck CH, Fowler PJ, Nott L. The results of fasciotomy in the management of chronic exertional compartment syndrome. Am J Sports Med. 1988;16:224.PubMedCrossRef

91.

Styf JR, Körner LM. Chronic anterior-compartment syndrome of the leg. Results of treatment by fasciotomy. J Bone Joint Surg Am. 1986;68:1338.PubMed

92.

van Zoest WJ, Hoogeveen AR, Scheltinga MR, et al. Chronic deep posterior compartment syndrome of the leg in athletes: postoperative results of fasciotomy. Int J Sports Med. 2008;29:419.PubMedCrossRef

Title: Nonatherosclerotic PAD: Approach to Exertional Pain in the Lower Extremities
Authors: Ari J. Mintz
Ido Weinberg
Publication date: 01-08-2015
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 8/2015
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-015-0622-8

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties